Florida International University (FIU) is pursuing a business partner interested in developing and commercializingsustained release antivirals for the treatment and prevention of HIV-AIDS. FIU inventors have developed a novel approach for co-encapsulation of AntiHIV drugs Tenofovir and Vorinostat using a magnetically-guided, layer-by-layer nanocarrier for the treatment of NeuroAIDS.
The proposed approach is anticipated to overcome many of the physiological barriers to activate latent viruses in the central nervous system and deliver drugs across the blood brain barrier (BBB) in a sustained manner to eradicate viruses. The movement of magnetic nanoparticles (MNP) can be “remote controlled” for its effective penetration across the BBB by applying an external magnetic force. Complimentarily, the layer-by-layer arrangement of drugs on MNP provides sustained drug release reducing the need of repeated dosage and potentially improving the patient’s compliance to the HIV therapy.
We are looking for a business partner to further develop and commercialize this technology as a viable alternative to commercially available methods; and to implement as an effective method for HIV therapy and easier for the patient to adhere to.
This is the first demonstration of nanotechnology use in latent virus activation and killing, thus, it provides a direction for more effective HIV therapy in the future.
- Offers a formulation that leads to better therapeutic compliance and better patient management.
- Provides for control of the movement of magnetic nanoparticles by remotely applying an external magnetic force and facilitating effectively penetrate across the blood brain barrier.
- Diminishes the need of multiple administration of drugs by providing a layer-by-layer assembly of nanoparticles that ensures a sustained release of drugs.
For additional information about this technology opportunity, please contact Elizabeth Garami at email@example.com or by phone at 305-348-0008 and ask about record IP 1412.